...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New shares issued?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Great answer BDAZ. That is the way I have heard it many many times. It could be sold as ZCC but most likely as ZEL or just the molecules protecting the patent for ZEN3694 packaged in a newco and then the newco sold and ZCC retaining the royalty.

tada

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply